Literature DB >> 8626831

Vasopressin receptor expression and mutation analysis in corticotropin-secreting tumors.

P L Dahia1, A Ahmed-Shuaib, R A Jacobs, S L Chew, J Honegger, R Fahlbusch, G M Besser, A B Grossman.   

Abstract

Vasopressin is an important regulator of hypothalamo-pituitary-adrenal axis activation, primarily acting through the V3 receptor (V3R). Many patients with ACTH-secreting pituitary adenomas, but not normal individuals, respond to desmopressin, a relatively V2-specific vasopressin agonist, with increased ACTH and cortisol levels. We have searched for mutations of the V3R gene in ACTH-secreting pituitary adenomas and one ectopic ACTH-secreting tumor. No abnormalities were found in 12 tumors studied by PCR-single strand conformation polymorphism (PCR-SSCP) analysis. We then verified by RT-PCR whether the response to desmopressin was due to overexpression of the V3R or abnormal expression of the V2R in the pituitary tumor. We found that the V2R gene was expressed in a number of corticotroph tumors and in the ACTH-secreting ectopic tumor, and that the V3R gene appears to be overexpressed in these tumors. We conclude that V3R mutations are unlikely to be present in the ACTH-secreting tumors we examined, but that the V2R gene is expressed in the majority of the samples tested, and the V3R is expressed in all of these tumors. We speculate that the response to the desmopressin test observed in patients with Cushing's disease may be due to abnormal expression of V3R or V2R in ACTH-secreting tumors.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8626831     DOI: 10.1210/jcem.81.5.8626831

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  13 in total

1.  GHRP-6 is able to stimulate cortisol and ACTH release in patients with Cushing's disease: comparison with DDAVP.

Authors:  J H A Oliveira; J G H Vieira; J Abucham; A M J Lengyel
Journal:  J Endocrinol Invest       Date:  2003-03       Impact factor: 4.256

Review 2.  Genetics of vasopressin receptors.

Authors:  Marc Thibonnier
Journal:  Curr Hypertens Rep       Date:  2004-02       Impact factor: 5.369

3.  The Gene of the Ubiquitin-Specific Protease 8 Is Frequently Mutated in Adenomas Causing Cushing's Disease.

Authors:  Luis G Perez-Rivas; Marily Theodoropoulou; Francesco Ferraù; Clara Nusser; Kohei Kawaguchi; Constantine A Stratakis; Fabio Rueda Faucz; Luiz E Wildemberg; Guillaume Assié; Rudi Beschorner; Christina Dimopoulou; Michael Buchfelder; Vera Popovic; Christina M Berr; Miklós Tóth; Arif Ibrahim Ardisasmita; Jürgen Honegger; Jerôme Bertherat; Monica R Gadelha; Felix Beuschlein; Günter Stalla; Masayuki Komada; Márta Korbonits; Martin Reincke
Journal:  J Clin Endocrinol Metab       Date:  2015-05-05       Impact factor: 5.958

Review 4.  The Treatment of Cushing's Disease.

Authors:  Rosario Pivonello; Monica De Leo; Alessia Cozzolino; Annamaria Colao
Journal:  Endocr Rev       Date:  2015-06-11       Impact factor: 19.871

5.  ACTH and cortisol responses to ghrelin and desmopressin in patients with Cushing's disease and adrenal enlargement.

Authors:  D Miljic; M Joksimovic; M Doknic; M Ivovic; M Djurovic; S Pekic; M Tancic; I Soldatovic; M Stojanovic; Dj Nale; Dj Macut; S Damjanovic; V Popovic
Journal:  J Endocrinol Invest       Date:  2010-02-05       Impact factor: 4.256

Review 6.  Cushing's disease: a surgical view.

Authors:  D K Lüdecke; J Flitsch; U J Knappe; W Saeger
Journal:  J Neurooncol       Date:  2001-09       Impact factor: 4.130

Review 7.  The molecular biology of pituitary tumors: a personal perspective.

Authors:  Ashley B Grossman
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

8.  The value of prolactin in inferior petrosal sinus sampling with desmopressin stimulation in Cushing's disease.

Authors:  Xiaona Qiao; Hongying Ye; Xiaolong Zhang; Weiwei Zhao; Shuo Zhang; Bin Lu; Xuanchun Wang; Zhaoyun Zhang; Xi Wu; Min He; Xiaolong Zhao; Shiqi Li; Linuo Zhou; Yehong Yang; Renming Hu; Yiming Li
Journal:  Endocrine       Date:  2014-07-17       Impact factor: 3.633

9.  Tolvaptan-induced remission of primary palmar hyperhidrosis in a patient with ADPKD: a serendipitous finding.

Authors:  E Cuka; M Vespa; G Joli; P Manunta; T M Sciarrone Alibrandi
Journal:  J Nephrol       Date:  2021-02-08       Impact factor: 3.902

Review 10.  Exploiting cancer's phenotypic guise against itself: targeting ectopically expressed peptide G-protein coupled receptors for lung cancer therapy.

Authors:  Mahjabin Khan; Tao Huang; Cheng-Yuan Lin; Jiang Wu; Bao-Min Fan; Zhao-Xiang Bian
Journal:  Oncotarget       Date:  2017-06-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.